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Abstract 
A novel azido derivative of the di-(2-picolyl)amide (Dpam) ligand, namely 3-azido-N,N-
bis-pyridin-2-ylmethyl-propionamide (3), was prepared from 3-bromo-N,N-bis(pyridin-2-
ylmethyl)propanamide (2) with an excess of sodium azide in DMSO. 3 was then reacted, by 
by Cu(I)-catalysed [3+2] cycloaddition (often referred as “Click Chemistry”), with the 
previously reported alkyne-containing Peptide Nucleic Acid (PNA) monomer Fmoc-1-OtBu 
to give the Dpam-containing PNA monomer” (Fmoc-4-OtBu) in 44% yield. It was also 
demonstrated that 3 could be reacted by Click Chemistry, on the solid phase, to an alkyne-
containing PNA oligomer (Alkyne-PNA) to yield Dpam-PNA. Our attempts to complex 
Dpam-PNA with [NEt4]2[ReBr3(CO)3] and [99mTc(CO)3(H2O)3]+ are also discussed in detail.  
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Introduction 
Peptide nucleic acids (PNAs) are unnatural DNA analogues, which have been discovered 
nearly 20 years ago.1,2 Their uncharged pseudopeptide backbone is made of N-(2-
aminoethyl)glycine units which are linked via a methylene carbonyl to the four DNA 
nucleobases.1,3-5 PNAs has been investigated in various fields of research such as antisense6 
and antigene7  therapies, specific target-directed cellular and in vivo gene repair8 and  
biosensing.9 Moreover, there is a growing interest on the preparation of (multi-)metal-
containing PNA monomers/oligomers.10-18 These “metal” modifications are usually performed 
to add new functionalities and/or spectroscopic properties to PNAs.19-22 For example, 
ferrocene or rhenium derivatives have been conjugated to PNA sequences for electrochemical  
biosensing and fluorescence purposes, respectively.17,23 
From a more synthetic point of view, the metal complexes have been, up to very recently, 
mainly attached to the N-terminus of the PNA sequence or to a side-chain of an amino acid 
(usually the amino group of lysine), limiting therefore the possibility of positioning a metal 
complex at any site within the PNA oligomer. However, our groups have lately presented a 
general approach to modify PNA oligomers with metal complexes using the Cu(I)-catalysed 
[3+2] cycloaddition,24,25 which is often referred as “Click Chemistry”.10 In these reports, we 
have demonstrated that an alkyne-modified PNA monomer10 (Fmoc-1-OH, Figure 1) could 
be inserted anywhere within a PNA sequence before being subsequently reacted by Click 
Chemistry with an azido-containing metal complex.10,26 We have also recently extended this 
concept to an azido ligand, namely 2-azido-N,N-bis((pyridin-2-yl)methyl)ethanamine (Dpa-
N3, Figure 1), which was first coupled using Click Chemistry, on the solid phase, to an 
alkyne-containing PNA oligomer before being complexed with a 99mTc tricarbonyl 
derivative.27  
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Figure 1. Structures of Fmoc-1-OtBu, Fmoc-1-OH, Dpa-N3 and 3. 
 
In order to increase the range of ligands, which can be reacted by Click Chemistry, we have 
recently embarked on a program to prepare new azido derivatives of the 2,2´-dipicolylamine 
(Dpa) ligand. It was anticipated that these compounds could also be reacted by Click 
Chemistry to alkyne-containing PNA oligomers before being coordinated to Re/99mTc 
carbonyl complexes. The examples of successful preparations of Re-containing PNA 
oligomers are surprisingly scarce,23,26,28,29 whilst those of 99mTc-containing PNA oligomers 
are more common.19,27,29-34 Re tricarbonyl PNA bioconjugates can be used as IR 
spectroscopical biosensors for DNA/RNA sequences. Indeed, the presence of intense carbonyl 
absorptions in the 1800-2200 cm-1 region render possible the selective detection and even 
quantification of the metal-PNA bioconjugates by IR spectroscopy (carbonyl metallo immuno 
assay, CMIA).35-38 Our groups have also recently introduced metal carbonyl complexes as 
novel entities for RAMAN microscopy.39 99mTc-containing PNAs have also been prepared to 
be employed as bioimaging agents.19,31,40-44 
For the purpose of this work, we decided to use a di-(2-picolyl)amide (Dpam) derivative (3, 
Figure 1) as a coordination entity for Re/99mTc tricarbonyl complexes. Such compounds were 
shown to be excellent ligands for metal ions, especially for Cu(II), Cd(II) and Zn(II).45-57 
Noteworthy, Alsfasser, Vahrenkamp et al. have inserted such Dpam ligands to the side-chain 
of amino acids in order to introduce metal complexes in peptide frameworks for medicinal 
and biological applications.45,47,48,52,53,57 However, to the best of our knowledge, no Re or Tc 
tricarbonyl complexes coordinated to such ligands have been reported to date. 
 5
Herein, we report on the successful preparation of a novel azido-Dpam derivative, namely 
3-azido-N,N-bis-pyridin-2-ylmethyl-propionamide (3, Figure 1) and its subsequent couplings 
to the alkyne-containing PNA monomer Fmoc-1-OtBu and to a 17-mer alkyne-containing 
PNA oligomer (Alkyne-PNA) to give 4 and Dpam-PNA, respectively. Our attempts to 
complex Dpam-PNA with [NEt4]2[ReBr3(CO)3] and the [99mTc(CO)3(H2O)3]+ moiety are also 
discussed in detail. 
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Results and Discussion. 
The synthetic route towards the preparation of Fmoc-4-OtBu is summarised in Scheme 1. 
In brief, 3-bromo-N,N-bis(pyridin-2-ylmethyl)propanamide (2) was synthesised by reacting 
the commercially available di-(2-picolyl)amine (Dpa) with 3-bromopropionyl chloride in dry 
CHCl3. The presence of the expected compound was confirmed by NMR spectroscopy with 
the formation of two singlets at 4.74 and 4.77 ppm respectively in the 1H-NMR spectrum of 2, 
corresponding to the CO-N-CH2-pyridine protons. These protons are no longer magnetically 
equivalent due to the formation of the amide bond. The bromo group of 2 was then replaced 
by an azido group using an excess of sodium azide in DMSO to give 3. A sharp vibration 
band at 2102 cm-1 in the IR spectrum corresponding to the azide function validated the 
successful preparation of 3. The Dpam-containing PNA monomer Fmoc-4-OtBu could then 
be prepared, in a relatively good yield (44%), by reacting 3 with the previously described 
alkyne-containing PNA monomer10 (Fmoc-1-OtBu) in the presence of CuI and sodium 
ascorbate in a mixture of water and acetone. Instead of employing the usual combination of a 
Cu(II) salt and a reductant such as sodium ascorbate to form, in situ, the required Cu(I) 
species coordinating the alkyne function, CuI was used in this reaction. It was anticipated that 
this substitution could prevent the complexation of the Dpa ligand of 3 with Cu(II), which 
would have eventually avoided the formation of the desired Fmoc-4-OtBu. Moreover, to 
avoid the oxidation of Cu(I), sodium ascorbate was added to the reaction mixture and the 
reaction was carried out under an argon atmosphere. The presence of Fmoc-4-OtBu was 
ascertained by ESI-MS spectrometry with a peak at 773.29 m/z ascribed to [M+H]+. 
Furthermore, as expected, the 1H NMR spectrum of Fmoc-4-OtBu, which is quite 
complicated due to the presence of rotamers, no longer contains the alkyne proton peaks at 
1.72 and 1.88 ppm respectively, which are present in the 1H-NMR spectrum of Fmoc-1-OtBu 
(see Figures S1 and S2 in the SI for the 1H- and 13C-NMR spectra of Fmoc-4-OtBu).10 
However, a new signal at approximatively 7.40 ppm corresponding to the proton of the 
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triazole ring is observed in the 1H-NMR spectrum of Fmoc-4-OtBu. These data together 
unambiguously confirmed the formation of Fmoc-4-OtBu.  
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Scheme 1. Preparation of Fmoc-4-OtBu. i) Br(CH2)2COCl, CHCl3, 100%; ii) NaN3, 
DMSO, 31%; iii) Fmoc-1-OtBu, CuI, sodium ascorbate, acetone:H2O 2:1 V:V, 44%. 
 
Due to the promising results obtained on the PNA monomer, we attempted to generalise 
this concept to a PNA oligomer. To do so, a 17-mer PNA oligomer containing the synthon 1 
(Alkyne-PNA) was synthesised on a TentaGel R Fmoc-Lys(Boc)-RAM resin using Fmoc-
Bhoc-protected PNA monomers (see Table 1 for a summary of the PNA oligomers prepared 
during the course of this work). The C-terminal lysine residue was introduced to enhance 
solubility58 and the glycine residue was inserted at the N-terminus of the PNA sequence to 
avoid any N-acyl transfer reactions.59 A spacer was also incorporated on each side of synthon 
1 to avoid any steric hindrance. The resin containing Alkyne-PNA was then transferred into a 
fritted syringe and swollen with DMF for 1h. Using similar reaction conditions as those 
recently reported by our group,27 the alkyne-containing PNA oligomer could be 
functionalised, on the solid phase, with 3 to give Dpam-PNA. The PNA oligomer was then 
cleaved from the resin with a mixture of TFA:TIS:H2O 95:2.5:2.5 (V/V/V). After HPLC 
purification, both the success of the click chemistry reaction and the purity of the oligomer 
were determined by ESI-MS, MALDI-TOF and LC-MS (see experimental section for more 
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details). As expected, peaks at m/z 1422, 1138, 948, 813, 711, 632 and 569 ascribed to 
[M+4H]4+, [M+5H]5+, [M+6H]6+, [M+7H]7+, [M+8H]8+, [M+9H]9+ and [M+10H]10+, 
respectively  were observed in the ESI-MS spectrum (see Figure S3 in the SI for the ESI-MS 
spectrum of Dpam-PNA). Despite great care during the HPLC purification, a very small 
amount of a Dpam-PNA oligomer missing one G base (MM-291) and of a Dpam-PNA 
oligomer missing both one G base and one T base (MM-291-266) are evident in the ESI-MS 
spectrum of the “pure fraction” of Dpam-PNA. The presence of these two extra oligomers 
were confirmed by MALDI-TOF spectrometry with a major peak at m/z 5682.9 corresponding 
to [M+H]+ and two minor peaks at m/z 5391.6 and 5127.3 corresponding to [M+H-G]+ and 
[M+H-G-T]+, respectively (see Figure S4 in the SI for the MALDI-TOF spectrum of Dpam-
PNA). These observations are not very surprising as it is well-known that the purification of 
closely related PNA oligomers is extremely difficult. Nonetheless, the purity of Dpam-PNA 
is high enough to be used for the next synthetic step (see Figure S5 in the SI for the HPL 
chromatogram of Dpam-PNA). 
 
Table 1. Summary of the PNA oligomers prepared in this work 
Name PNA Sequence 
Alkyne-PNA H-gly-gcggctgtgcggtgcgg-Spacer-1-Spacer-Lys-NH2 
Dpam-PNA H-gly-gcggctgtgcggtgcgg-Spacer-4-Spacer-Lys-NH2 
 
With Dpam-PNA in hand, we have then focused our attention on examining the feasibility 
of complexing the Dpam moiety with [NEt4]2[ReBr3(CO)3]. However, as no Re tricarbonyl 
complexes coordinated to such ligands have been reported to date, we initially investigated 
the behaviour of 3 and Fmoc-4-OtBu upon metal complexation in methanol. Alfasser et al. 
have reported in detail the methanolysis of such ligands when reacted with Cu(II) salts,45,47,53 
however they did not observe such phenomena with Cd(II) salts.53 Using standard 
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experimental conditions for the complexation of the Re tricarbonyl moiety with similar 
ligands,26 namely refluxing in methanol for 3h using a 1:1 stoechiometry between the ligand 
and [NEt4]2[ReBr3(CO)3], we discovered that a similar methanolysis of 3 occurred, as 
described in Scheme 2. ESI-MS analysis of the sticky yellow oil crude product confirmed the 
methanolysis with two intense peaks at m/z 469.9 and 130.1, corresponding to the expected 
degradation products [Re(CO)3(Dpa)]+ 60 and [MeOOC(CH2)2N3 + H]+ 61, respectively (see 
Figure S6 in the SI). A similar behaviour was observed when Fmoc-4-OtBu was refluxed in 
methanol with [NEt4]2[ReBr3(CO)3] (Scheme 2). However, in this case, we were able to 
detect the presence of a small amount of the complex [Re(CO)3(Fmoc-4-OtBu)]Br by 
MALDI-TOF spectrometry. The expected isotopic pattern for [Re(CO)3(Fmoc-4-OtBu)]+ 
was found at approximatively m/z 1043 (see Figure S7 in the SI). 
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Scheme 2. Reaction of 3 and Fmoc-4-OtBu with [NEt4]2[ReBr3(CO)3] in methanol 
engendering methanolysis. i) [NEt4]2[ReBr3(CO)3], MeOH, reflux, 3h.  
Due to these findings, we have decided to perform the labelling of Dpam-PNA with 
[NEt4]2[ReBr3(CO)3] in acetonitrile instead of methanol. A similar stoichiometric ratio to that 
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successfully used for the labelling of a PNA oligomer with [99mTc(CO)3(H2O)3]+, namely an 
excess of the PNA oligomer compared to the metal ion (100:1), was employed.27 However, 
after 1h at 80°C, no complexation (nor hydrolysis) of Dpam-PNA could be detected by 
MALDI-TOF spectrometry. Increasing the reaction time and the amount of the Re complex 
(up to a 1:1 ratio PNA:metal ion) as well as addition of water did not lead to any significant 
improvements. The only detectable peaks in the MALDI-TOF spectrum were those 
corresponding to the starting materials (see experimental section). However, when the 
labelling of Dpam-PNA with the [99mTc(CO)3(H2O)3]+ moiety was investigated, small 
amounts of 99mTc complexation could be detected, probably due to the higher sensitivity of 
the -detector. As shown in Figure 2, after a reaction time of 1h at 70°C, the most abundant 
99mTc species present in solution (91 %) is the unreacted [99mTc(CO)3(H2O)3]+ (tR = 5.32 min). 
The three other peaks at tR = 3.33, 17.20 and 18.97 min correspond to [TcO4]- (2%), the 
expected 99mTc PNA oligomer [99mTc(CO)3(Dpam-PNA)]+ (4%) and the 99mTc degradation 
product [99mTc(CO)3(Dpa)]+ (3%), respectively. The assignment of the later peak could be 
ascertained by comparing the HPLC trace ( detection) of the reaction of [Tc(CO)3(H2O)3]+ 
with Dpa·3HCl (see Figure S8 in the SI).62 It should be noted that a definitive proof of the 
formation of [99mTc(CO)3(Dpam-PNA)]+ cannot be given due to the absence of the cold Re 
analogue. However, the retention time (tR =17.20) corroborates with that previously described 
for a Dpa-containing PNA oligomer.27 Indeed, [99mTc(CO)3(Dpa)]+ was found to be more 
lipophilic than the bioconjugates itself [99mTc(CO)3(Dpam-PNA)]+. Furthermore, upon fac-
[Tc(CO)3]+ complexation of Dpam-PNA, [99mTc(CO)3(Dpam-PNA)]+ also became more 
hydrophilic (shift from 20.75 to 17.20 min in the HPL chromatograms). Noteworthy, the 
unreacted PNA oligomer Dpam-PNA could still be detected by HPLC (UV detection) after 
1h at 70°C, emphasising the stability of PNAs even under harsh conditions (see Figure S9 in 
the SI). The presence of [99mTc(CO)3(Dpa)]+ underscores that hydrolysis is difficult to avoid. 
It is worth mentioning that Alberto et al. have also encountered a C-N bond cleavage of one 
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of their ligands upon 99mTc complexation.63 All in all, the complexation yields of Dpam-PNA 
with both [NEt4]2[ReBr3(CO)3] and the [99mTc(CO)3(H2O)3]+ moiety are either non-existent or 
extremely poor. These findings suggest that Dpam is not an appropriate ligand for both IR 
biosensing or radiolabelling purposes, at least under the experimental conditions employed in 
this study. 
 
Figure 2. HPLC trace ( detection) of the reaction of [Tc(CO)3(H2O)3]+ with Dpam-PNA 
after 60 min at 70°C. 
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Conclusions 
In this study, we have demonstrated, to the best of our knowledge, the first successful 
insertion of a modified di-(2-picolyl)amide (Dpam) ligand into both a PNA monomer and a 
17-mer PNA oligomer using click chemistry methodology. Furthermore, it was shown that 
two Dpam-containing derivatives, 3 and Fmoc-4-OtBu, behave similarly upon complexation 
with Re(I) or with Cu(II) with regards of methanolysis. Indeed, upon reaction of the two latter 
compounds with [NEt4]2[ReBr3(CO)3] in methanol, the amide bond of the two expected Re(I) 
complexes are cleaved, as previously observed by Alsfasser and co-workers upon 
complexation of similar ligands with Cu(II). However, no complexation or hydrolysis of 
Dpam-PNA could be detected by MALDI-TOF spectrometry when Dpam-PNA was reacted 
with [NEt4]2[ReBr3(CO)3] for 1h at 80°C in acetonitrile. On the contrary, when the labelling 
of Dpam-PNA with the [99mTc(CO)3(H2O)3]+ moiety was examined, the expected 99mTc PNA 
oligomer [99mTc(CO)3(Dpam-PNA)]+ and the 99mTc degradation product 
[99mTc(CO)3(Dpa)]+  could be detected, although the most abundant 99mTc species present in 
solution was by far the unreacted [99mTc(CO)3(H2O)3]+. The extremely low yields obtained for 
both the Re and 99mTc complexation suggest that Dpam is not a suitable ligand for both IR 
biosensing or radiolabelling purposes under the experimental conditions presented in this 
study.  
In a more general term, this work is another contribution towards the preparation of novel 
metal-containing PNA oligomers, which have shown great promises in various fields of 
research ranging from biosensing to nuclear therapy or diagnostics.19 Moreover, the recent 
discovery of Re tricarbonyl complexes as potential anticancer agents is further 
encouragements to prepare new Re-PNA oligomers, where the PNAs could be used as 
specific transporters to deliver metallo-chemotherapeutics.64 Alternatively, the Re complexes 
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could serve as fluorescent probes and not as anticancer agents, as recently demonstrated in a 
biological context.23,26,65,66 
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Experimental Section 
Materials. All chemicals were of reagent grade quality or better, obtained from commercial 
suppliers and used without further purification. Solvents were used as received or dried over 4 
Å molecular sieves. 
Instrumentation and methods. 1H- and 13C-NMR spectra were recorded in deuterated 
solvents on a Bruker DRX 400 spectrometer at 30°C. The chemical shifts, δ, are reported in 
ppm (parts per million). The residual solvent peaks have been used as an internal reference. 
The abbreviations for the peak multiplicities are as follows: s (singlet), d (doublet), dd 
(doublet of doublets), t (triplet), q (quartet), m (multiplet) and br (broad). Infrared spectra 
were recorded on a ATR unit using a Bruker Tensor 27 FTIR spectrophotometer at 4 cm-1 
resolution. Signal intensity is abbreviated br (broad). ESI mass spectra were recorded on a 
Bruker Esquire 6000. The matrix-assisted laser desorption/ionization time of flight mass 
spectrometry (MALDI-TOF) mass spectra were measured on a Bruker Daltonics Autoflex. 
The experiments were performed in linear mode with positive polarity using sinapinic acid or 
-cyano-4-hydroxy-cinnamic acid as the matrix. HPLC purification of Dpam-PNA was 
performed on a Merck-Hitachi L-7000 system equipped with a diode array UV/Vis 
spectrometer and an Agilent Zorbax 300SB-C18 semi-prep column (5 μm particle size, 300 Å 
pore size, 250 x 9.4 mm. Flow rate: 4 ml min-1). The runs were performed with a linear 
gradient of A (distilled water containing 0.1 % v/v TFA) and B (acetonitrile (Sigma-Aldrich 
HPLC-grade), containing 0.1 % v/v TFA). Preparative runs: t = 0 min 5 % B. t = 12 min 15 % 
B. t = 32 min 40 % B. t = 50 min 80 % B. t = 51 min 100 % B. t = 56 min 100 % B. t = 61 
min 5 % B. LC-MS spectrum of Dpam-PNA was measured on a AcquityTM from Waters 
system equipped with a PDA detector and an auto sampler using an Agilent Zorbax 300SB-
C18 analytical column (3.5 μm particle size, 300 Å pore size, 150 x 4.6 mm). This LC was 
coupled to an Esquire HCT from Bruker (Bremen, Germany) for the MS measurements. The 
LC run (flowrate: 0.3 mL min-1) was performed with a linear gradient of A (distilled water 
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containing 0.1 % v/v formic acid) and B (acetonitrile (Sigma-Aldrich HPLC-grade), 
containing 0.1 % v/v formic acid); t = 0 min 5 % B. t = 3 min 5 % B. t = 17 min 100 % B. t = 
20 min 100 % B. t = 25 min 5 % B. 
Synthesis and Characterisation. 
[NEt4]2[ReBr3(CO)3]. [NEt4]2[ReBr3(CO)3] was prepared following the procedure 
published by Alberto et al. The spectroscopic data of the products matched that reported 
previously.67 
Dpa.3HCl. Dpa.3HCl was prepared following the procedure published by Larsen et al.68 
The spectroscopic data of the products matched that reported previously.68  
{[2-(9H-Fluoren-9-ylmethoxycarbonylamino)-ethyl]-pent-4-ynoyl-amino}-acetic acid 
tert-butyl ester (Fmoc-1-OtBu).  Fmoc-1-OtBu was prepared following the procedure 
published by Gasser et al.10  The analytical data match what previously reported.10  
2-(N-(2-(((9H-fluoren-9-yl)methoxy)carbonylamino)ethyl)pent-4-ynamido)acetic acid 
(Fmoc-1-OH). Fmoc-1-OH was prepared following the procedure published by Gasser et 
al.10  The analytical data match what previously reported.10  
3-Bromo-N,N-bis(pyridin-2-ylmethyl)propanamide (2). To a stirred solution of di-(2-
picolyl)amine (2.50 g, 12.10 mmol) in dry CHCl3 (125 mL) cooled to 0°C was added 3-
bromopropionyl chloride  (2.18 g, 12.10 mmol) under a nitrogen atmosphere. The reaction 
mixture was stirred for 30 minutes at 0°C and then for 16h at room temperature. The reaction 
mixture turned light green and then yellow. An aqueous solution of Na2CO3(sat) (100 mL) was 
then added to this mixture which was then stirred for 5 min. The phases were separated and 
the aqueous phase was back-extracted with CHCl3 (2x150 mL). The combined organic phases 
were dried over Na2SO4, filtered and the solvent removed under vacuo to give a brown-orange 
oil that is pure enough to be used for the next synthetic reaction step. Yield: 4.04g (100 %). 
Characterisation Data. 1H-NMR Spectrum (CDCl3):  3.07 (t, 3J = 7.0 Hz, 2H, NCO-CH2-
CH2), 3.67 (t, 3J = 7.0 Hz, 2H, CH2-CH2Br), 4.74 (s, 2H, CO-N-CH2-pyr), 4.77 (s, 2H, CO-N-
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CH2-pyr), 7.14 (m, 2H, CH pyr), 7.29 (m, 2H, CH pyr), 7.61 (m, 2H, CH pyr), 8.50 (m, 2H, 
CH pyr).13C-NMR Spectrum (CDCl3):  27.37 (CH2-CH2-Br), 36.41 (CO-CH2-CH2Br), 51.37 
(N-CH2-pyr), 52.83 (N-CH2-pyr), 121.05 (CH pyr), 122.28 (CH pyr), 122.50 (CH pyr), 
122.54 (CH pyr), 136.69 (CH pyr), 136.75 (CH pyr), 149.04 (CH pyr), 149.87 (CH pyr), 
156.07 (C pyr), 156.99 (C pyr), 171.03 (NCO). Electrospray Mass Spectrum (m/z): 254.1 [M-
Br]+ (100%). 
3-Azido-N,N-bis(pyridin-2-ylmethyl)propanamide (3). Sodium azide (0.68 g, 10.45 
mmol) was partially dissolved while stirring in dry DMSO (20 mL) for 1h30 under a nitrogen 
atmosphere. 2 (0.70 g, 2.09 mmol) diluted in dry DMSO (5 mL) was added to the solution 
and, within minutes, the remaining sodium azide dissolved. The reaction was stirred for 22h at 
room temperature. The reaction mixture was then diluted with H2O (45 mL) and the product 
extracted with ethyl acetate (2 x 75 mL). The combined organic phases were washed with 
brine (3 x 40 mL), dried with Na2SO4, filtered and concentrated under vacuum to give a 
brown oil. The product was purified by column chromatography on silica with ethyl 
acetate:methanol 10:1 as the eluent to give 3 as a slightly yellow oil. It is to point out that two 
spots are observed by TLC (Rfs = 0.28 and 0.32) while the product looks nearly perfectly 
pure by both 1H- and 13C-NMR spectroscopy. Yield: 0.19 g (31 %). Characterisation Data. 
Major IR bands (, cm-1): 3051 w, 3009 w, 2934 w, 2102 m, 1733 m, 1645 s, 1591 m, 1570 
m, 1474 m, 1434 s, 1371 w, 1359 w,  1290 m, 1268 m, 1240 m, 1198 m, 1148 w, 1098 w, 
1047 m, 994 m, 969 w, 937 w, 902 w, 839 w, 751 s, 634 m, 617 m. 1H-NMR Spectrum 
(CDCl3):  2.76 (t, 3J = 6.5 Hz, 2H, NCO-CH2-CH2), 3.66 (t, 3J = 6.5 Hz, 2H, CH2-CH2Br), 
4.70 (s, 2H, CO-N-CH2-pyr), 4.77 (s, 2H, CO-N-CH2-pyr), 7.15 (m, 2H, CH pyr), 7.29 (m, 
2H, CH pyr), 7.62 (m, 2H, CH pyr), 8.51 (m, 2H, CH pyr). 13C-NMR Spectrum (CDCl3):  
32.65 (NCO-CH2-CH2), 47.28 (CH2-CH2N3), 51.46 (N-CH2-pyr), 52.94 (N-CH2-pyr), 121.02 
(CH pyr), 122.32 (CH pyr), 122.57(CH pyr), 122.60 (CH pyr), 136.69 (CH pyr), 136.80 (CH 
pyr), 149.14 (CH pyr), 149.95 (CH pyr), 156.22 (C pyr), 157.12 (C pyr), 171.04 (NCO). 
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Electrospray Mass Spectrum (m/z): 254.1 [M-N3]+ (10%), 297.1 [M+H]+ (100%), 319.1 
[M+Na]+ (10%). 
{(3-{1-[2-(Bis-pyridin-2-ylmethyl-carbamoyl)-ethyl]-1H-[1,2,3]triazol-4-yl}-propionyl)-
[2-(9H-fluoren-9-ylmethoxycarbonylamino)-ethyl]-amino}-acetic acid tert-butyl ester 
(Fmoc-4-OtBu). To a suspension of 3 (70 mg, 0.236 mmol) and Fmoc-1-OtBu (100 mg, 
0.236 mmol) in a mixture of acetone (3 mL) and water (1.5 mL), CuI (9 mg, 47.2 µmol) and 
sodium ascorbate (19 mg, 94.0 µmol) were successively added. The reaction mixture was 
stirred for 16h under an Ar atmosphere at room temperature. After evaporation of the 
solvents, dichloromethane (40 mL) was added and the solution was then washed twice with 
water (2x10 mL). The organic yellow phase was then dried over Na2SO4, filtered and 
evaporated to dryness. The orange residue was purified by chromatography column on silica 
with ethyl acetate:methanol (10:1) as the eluent to give Fmoc-4-OtBu as a slightly yellow oil. 
Yield: 80 mg (44%). Characterisation Data. 1H-NMR spectrum (CDCl3) δ: 1.42 (s, 9H, tert-
Butyl), 2.55 (m, 2H, Ctriazole-CH2-CH2-CO), 2.95 (m, 2H, Ctriazole-CH2-CH2-CON), 2.99 - 3.10 
(m, NCO-CH2-CH2-Ntriazole), 3.27 (m, 2H, OCONH-CH2-CH2-N), 3.42 (m, 2H, OCONH-
CH2-CH2-N), 3.85 and 3.90 (d, rotamers, 2H, N-CH2-COOC(CH3)3), 4.05 - 4.17 (m, 1H, 
CFmoc-CH-CH2-OCON), 4.27 (m, 2H, CFmoc-CH-CH2-OCONH), 4.52 (d, rotamers, 4H, 
Cpyridine-CH2-N), 4.60 (m, NCO-CH2-CH2-Ntriazole), 6.95 (t, 3J = 8.00 Hz, 2H, CH pyridine), 
7.05 - 7.12 (m, 2H, CH pyridine), 7.19 - 7.25 (m, 2H, CH Fmoc), 7.27 - 7.35 (m, 2H, CH 
Fmoc), 7.40 (s, 1H, CH triazole), 7.49 - 7.58 (m, 4H, CH Fmoc and CH pyridine), 7.69 (d, 3J 
= 4.67 Hz, 2H, CH Fmoc), 8.40 (m, 2H, CH pyridine). 13C-NMR spectrum (CDCl3) δ: 21.10 
(Ctriazole-CH2-CH2-CON), 28.04 (tert-Butyl CH3), 31.90 (Ctriazole-CH2-CH2-CON), 33.62 
(NCO-CH2-CH2-Ntriazole), 47.76 (CFmoc-CH-CH2-OCON), 48.20 (OCONH-CH2-CH2-N), 
49.89 (OCONH-CH2-CH2-N), 49.95 (NCO-CH2-CH2-Ntriazole), 51.43 (Cpyridine-CH2-N), 52.79 
(N-CH2-COOC(CH3)3), 67.00 (CFmoc-CH-CH2-OCONH), 82.94 (N-CH2-COOC(CH3)3), 
119.90 (CH Fmoc), 121.21 (CH pyridine), 122.46 (CH triazole), 122.63 (CH pyridine), 
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125.14 (CH Fmoc), 127.06 (CH Fmoc), 127.67 (CH Fmoc), 136.70 (CH pyridine), 141.27 (C 
Fmoc), 143.91 (C Fmoc), 146.31 (C triazole), 149.94 (CH pyridine), 155.80 (OCONH), 
156.96 (C pyridine), 169.00 and 170.00 (rotamers, N-CH2-COOC(CH3)3), 170.64 (NCO-CH2-
CH2-Ntriazole), 172.53 and 173.35 (rotamers, Ctriazole-CH2-CH2-CON), ESI-MS [m/z]: 773.29 
[M+H]+. 
Attempt of preparation of the Re(CO)3 complex of 3 ([Re(CO)3(3)]Br). 
[NEt4]2[ReBr3(CO)3] (0.259 g, 0.34 mmol) and 3 (0.100 g, 0.34 mmol) were refluxed in 
deoxygenated methanol (40 mL) under an Ar atmosphere for 3 hours. The mixture was then 
cooled to room temperature and evaporated to dryness to give a sticky yellow oil. ESI-MS 
analysis of the crude product confirmed the methanolysis with two intense peaks at m/z 469.9 
and 130.1 corresponding to the expected compounds [Re(CO)3(Dpa)]+ and 
[MeOOC(CH2)2N3 + H]+, respectively (see Figure S5 in the SI). These compounds were not 
isolated. 
Attempt of preparation of the Re(CO)3 complex of Fmoc-4-OtBu ([Re(CO)3(Fmoc-4-
OtBu)]Br). To a stirring solution of [NEt4]2[Re(CO)3Br3] (79.33 mg, 0.104 mmol) in 
deoxygenated methanol (15 mL), Fmoc-4-OtBu (80 mg, 0.104 mmol), dissolved in 
deoxygenated methanol (1.5 mL), was added under an Ar atmosphere. The reaction mixture 
was refluxed for 3 hours. The mixture was then cooled to room temperature and evaporated to 
dryness to give a yellow oil. ESI-MS analysis of the crude product confirmed the 
methanolysis with two intense peaks at m/z 470.0 and 628.2 corresponding to the expected 
compounds of methanolysis [Re(CO)3(Dpa)]+ and Fmoc-5-OtBu, respectively. These 
compounds were not isolated. However, a small amount of the expected compound 
[Re(CO)3(Fmoc-4-OtBu)]Br could be detected by MALDI-TOF with peaks at m/z 1041.32 
(53%), 1042.32 (36%), 1043.32 (100%), 1044.32 (55%) and 1045.33 (26 %) corresponding to 
[M+] (see Figure S7 in the SI for the isotopic pattern). 
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Synthesis of Alkyne-PNA. Alkyne-PNA was synthesised using an automated Expedite 
8909 nucleic acid synthesiser (Applied Biosystems) adapted for PNA synthesis. Synthesis 
was performed on a 2-mol scale with Tentagel R Ram-Lys(Boc)Fmoc resin (0.20 mmol/g) 
from Rapp Polymer using Fmoc/Bhoc-protected monomers from commercial suppliers (Link 
Technologies, Lanarkshire, Scotland). Synthon Fmoc-1-OH, dissolved in N-
methylpyrrolidone (NMP), was inserted in one of the free positions of the synthesiser and a 
double coupling was applied in order to ensure a full coupling.  
Synthesis of Dpam-PNA. The resin containing Alkyne-PNA was transferred into a fritted 
syringe. The resin was then swollen with DMF for 1h. 3 (1.7 mg, 6 mol) and CuI (0.78 mg, 
2 mol) were then introduced into the syringe (from the top). Afterwards, a mixture of 
ethyldiisopropylamine (54 L) and DMF (400 l) were aspired up the syringe and the mixture 
was shaken for 2 days at room temperature in the absence of light and under an argon 
atmosphere. The resin was then washed with DMF (5x), CH3CN (5x), CH2Cl2 (5x) and DMF 
(5x) successively. Before cleavage, the resin was shrunk with methanol and dried under high 
vaccum. The PNA oligomer was then cleaved using a mixture of trifluoroacetic 
acid:water:triisopropylsilane 95:2.5:2.5 [3 x 400 l (1h30 each)]. The resulting solution was 
first evaporated to dryness before being precipitated with ice-cold ether. The solid was 
centrifuged, washed with ice-cold ether and finally air dried. The obtained crude oligomer 
was then purified by RP-HPLC and finally characterised by ESI-MS spectrometry. The purity 
of Dpam-PNA was checked by LC-MS. Despite great care taken during the HPLC 
purification, a very small amount of a Dpam-PNA oligomer missing one G base (MM-291) 
and of a Dpam-PNA oligomer missing both one G base and one C base (MM-291-266) are 
noticeable in the ESI-MS spectrum of Dpam-PNA. Characterisation of Dpam-PNA. HPLC: 
tR = 10.2 min. ESI-MS: m/z 1422 [M+4H]4+, 1138 [M+5H]5+, 948 [M+6H]6+, 813 [M+7H]7+, 
711 [M+8H]8+, 632 [M+9H]9+ and 569 [M+10H]10+. MALDI-TOF: m/z 5682.9 [M+H]+,  
5391.6 [M+H-G]+, 5127.3 [M+H-G-T]+. 
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PNA concentration determination. The PNA strand concentration was measured on a 
NanoDrop 2000 spectrophotomer by means of the absorption at 260 nm using the incremental 
extinction coefficients of the PNA nucleobases (PNA,A = 13700 M-1cm-1, PNA,G = 11700 M-
1cm-1, PNA,C = 6600 M-1cm-1, PNA,T = 8600 M-1cm-1).2 An extinction coefficient of 260 = 
6099 M-1cm-1 was taken for the Dpam moiety. This value was determined for a similar Dpa 
derivative.27 
Attempt of preparation of the Re(CO)3 complex of Dpam-PNA ([Re(CO)3(Dpam-
PNA]Br). [NEt4]2[Re(CO)3Br3] (1.85.10-10 g, 0.24 μmol) and Dpam-PNA (0.14 μg, 24.0 
μmol) were reacted in acetonitrile (60 μl) for 1 h at 80 °C. The reaction mixture was then 
analysed by MALDI-TOF mass spectrometry.  Characterisation of the reaction mixture. 
MALDI-TOF: m/z 5683.1 [M(Dpam-PNA)+H]+, 5391.1 [M(Dpam-PNA)+H-G]+, 5125.4 
[M(Dpam-PNA)+H-G-T]+,  5910.4 [M(Dpam-PNA)+SA]+ , 6131.9 [M(Dpam-PNA)+2SA]+. 
Radiolabeling experiments of Dpa and Dpam-PNA with 99mTc. Na[99mTcO4] was eluted 
from a 99Mo/99mTc generator, using 0.9% saline (107 MBq). With an Isolink kit 
(Mallinckrodt-Tyco, Inc.), the preparation of fac-[99mTc(CO)3(H2O)3]+ was performed 
according to a previously described procedure.69 The [99mTc(CO)3(H2O)3]+ solution was 
neutralised by the addition of 70 L of a 1M HCl solution. To label the Dpa chelator with 
99mTc, 100 L of a 10-2 M Dpa·3HCl PBS solution were added to 100 L of the 
[99mTc(CO)3(H2O)3]+ solution. The reaction was performed in a 1 ml Eppendorf tube at 95°C. 
After 20 min, the reaction was checked by HPLC. 
For the radiolabeling of Dpam-PNA, 70 µL (4.27·10-5 µmol)  of  Dpam-PNA dissolved in 
CH3CN were added to a 100 µL [99mTc(H2O)3(CO)3]+ solution. The reaction was performed 
in a nitrogen-purged 1 mL Eppendorf vial. The solution was heated for 60 minutes at 70°C. 
Afterwards, the reaction was checked by HPLC. 
HPLC analyses were performed on a Merck Hitachi LaChrom L 7100 pump coupled to a 
Merck Hitachi LaChrom L7200 tunable UV detector and a radiodetector, separated by a 
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Teflon tube, which causes about a 0.4 – 0.7 min delay compared to UV/vis detection. UV/vis 
detection was performed at 250 nm. The detection of radioactive 99mTc complexes was 
performed with a Berthold FlowStar LB513 radiodetector equipped with a NaI(Tl) 
scintillation detector. Separations were achieved on a Macherey-Nagel C18 reversed-phase 
column (Nucleosil 100 Å, 250 x 3 mm). The column was eluted with a flow rate of 0.5 ml 
min−1 using as eluents 0.1% TFA in H2O (solvent A) and methanol (solvent B) with a variable 
gradient (0–3 min, 100% A; 3 – 3.1 min, 0 to 25% B; 3.1–9 min, 25% B; 9–9.1 min, 25% B 
to 34% B; 9.1–20 min, 34% B to 100% B; 20–25 min, 100% B; 25–25.1 min 100% B to 
100% A; 25.1–30 min 100% A). 
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